Announcement of Licensing Agreement for Ophthalmic Treatment "DW-1001"
Dec 12, 2019
We are pleased to announce that we have entered into a licensing agreement today regarding the exclusive development, manufacturing, and sales rights for the ophthalmic treatment "DW-1001," developed by D. Western Therapeutics Institute, Inc. (hereinafter referred to as "DWTI") in Japan.
"DW-1001" was introduced to Japan by DWTI in 2015 from a UK-based company, and it has been under consideration for formulation and other developments. Please note that the specific disease targeted by this treatment remains undisclosed.
With the signing of this agreement, ROHTO Pharmaceutical will now take over the development of DW-1001 for the treatment of specific ophthalmic diseases in Japan, commencing with non-clinical trials..
We are actively exploring opportunities in the medical pharmaceuticals business and have been conducting various research activities in the field of ophthalmology. Moving forward, we will continue to provide products and services that benefit healthcare professionals in the ophthalmology sector and contribute to the eye health of individuals.
It is worth mentioning that the impact of this agreement on our current fiscal year's performance is expected to be minimal.
About DWTI
| (1) Name |
D. Western Therapeutics Institute, Inc. |
| (2) Adress |
18-11 Nishiki 1-chome, Naka-ku, Nagoya, Japan |
| (3) Representative |
President and Chief Executive Officer, Yuichi Hidaka |
| (4) Business Activities |
Pharmaceutical Research and Development |
| (5) Capital |
JPY 34 million (as of March 31, 2019) |